Lysosomal diseases are a family of over 50 disorders caused by defects in proteins critical for normal function of the endosomal/lysosomal system and characterized by complex pathogenic cascades involving progressive dysfunction of many organ systems, most notably the brain. Evidence suggests that compromise in lysosomal function is highly varied and leads to changes in multiple substrate processing and endosomal signalling, in calcium homoeostasis and endoplasmic reticulum stress, and in autophagocytosis and proteasome function. Neurons are highly vulnerable and show abnormalities in perikarya, dendrites and axons, often in ways seemingly unrelated to the primary lysosomal defect. A notable example is NAD (neuroaxonal dystrophy), which is characterized by formation of focal enlargements (spheroids) containing diverse organelles and other components consistent with compromise of retrograde axonal transport. Although neurons may be universally susceptible to NAD, GABAergic neurons, particularly Purkinje cells, appear most vulnerable and ataxia and related features of cerebellar dysfunction are a common outcome. As NAD is found early in disease and thus may be a contributor to Purkinje cell dysfunction and death, understanding its link to lysosomal compromise could lead to therapies designed to prevent its occurrence and thereby ameliorate cerebellar dysfunction.
Introduction
Lysosomal diseases were first described clinically and pathologically over 100 years ago and were subsequently defined and classified by biochemical analysis of stored materials, giving rise to a classification system that includes the mucopolysaccharidoses, glycosphingolipidoses, mucolipidoses, glycoproteinoses and so forth [1] . Articulation of the lysosomal disease concept by H.-G. Hers in 1965 [2] ushered in the discovery of individual lysosomal enzyme defects, followed subsequently by gene identification and mutation analysis [3] . This remarkable knowledge transition, from the era of clinical and pathological description to biochemical classification and to protein and gene discovery, has now turned towards emphasis of an entirely new research focus, appropriately named the Era of Pathogenesis [4] . That is, it is now clear that to truly understand (and particularly to treat) these and other inborn errors of metabolism, it is necessary to know far more than the identity of the gene and protein defects. What must be understood are the details of the intricate series of consequences that occur following the loss of a particular protein: the pathogenic cascade. And, importantly, this puzzle needs to be solved, not just generically, but rather for individual cell types, since the specifics of a disease cascade will probably vary depending Key words: autophagy, axonal spheroid, axoplasmic transport, lysosomal disease, Niemann-Pick type C disease, Purkinje cell. Abbreviations used: DCN, deep cerebellar nuclei; IS, initial segment; MLIV, mucolipidosis type IV; NAD, neuroaxonal dystrophy; NPC, Niemann-Pick type C; pcd, Purkinje cell degeneration; VN, vestibular nuclei. 1 To whom correspondence should be addressed (email steve.walkley@einstein.yu.edu).
on the metabolic signature of the cell in question. Since most lysosomal diseases exhibit brain dysfunction, a cell of particular interest is the neuron. Yet even here, as described below, there is ample evidence that neuronal subtypes often display dramatic differences in their response to a defect in a given lysosomal protein.
The pathogenic cascade affecting neurons
At least two-thirds of lysosomal diseases affect the brain, and many types of cellular defects have been described [5] . Although some have major impact on oligodendroglia and myelination of axons, leading to white matter lesions (the leukodystrophies, such as Krabbe disease or metachromatic leukodystrophy), most lysosomal disorders exhibit the largest impact on neurons and grey matter [1] . In addition to intraneuronal 'storage' affecting the endosomal/lysosomal system, other cellular changes include meganeurite formation, ectopic dendritogenesis, NAD (neuroaxonal dystrophy) and, ultimately, neurodegeneration. Although, in most diseases, neuronal storage in brain appears universal, in others, it may be restricted to highly select populations of neurons. In Fabry disease, for example, neuronal storage has been reported to be restricted primarily to select populations of neurons in nuclei of the amygdala, hypothalamus, brain stem and spinal cord [6] . Even in lysosomal diseases in which essentially all neurons show storage, some neuronal populations will exhibit specific vulnerabilities (e.g. ectopic dendritogenesis, axonal spheroids or early death) not evident in others. For any given lysosomal disease, the wide array of pathological changes observed in brain can be viewed as an example of divergence of effect, i.e. the outward manifestation of a complex and expanding disease cascade set in motion by the absence of function of a single protein. Importantly, in comparing different lysosomal diseases, one also typically finds evidence of a convergence of effect, i.e. the exact same cellular abnormalities often occur across many, although not necessarily all, lysosomal disorders [5] . Ectopic dendritogenesis, for example, has been documented principally in pyramidal neurons in primary ganglioside storage diseases, but also occurs in these same cells in some of the mucopolysaccharidoses and in the glycoproteinosis known as α-mannosidosis. For each of these, it appears linked in some manner to disturbances in the processing and resulting accumulation of glycosphingolipids [7, 8] . Interestingly, however, this phenomenon has never been reported to occur in any other type of neurological disease. Axonal spheroid formation, or NAD, likewise, is found in these and some other lysosomal disorders but predominates in GABAergic neurons of the cerebral cortex rather than pyramidal neurons, and is particularly abundant on Purkinje cells of the cerebellum [9] . In this case, as detailed below, there is no apparent linkage to any specifically identified storage compounds in perikarya, and thus the nature of the metabolic defect and pathogenic cascade that triggers the axonal compromise remains a mystery. Also, in contrast with ectopic dendritogenesis, there is evidence that spheroids very similar to those observed in lysosomal disease also occur in other neurological and genetic conditions, including Alzheimer's disease [10] .
Neuroaxonal dystrophy
Just as certain types of neurons show the presence of renewed dendrite growth (ectopic dendritogenesis) following lysosomal system derangement, other neurons exhibit highly conspicuous axonal alterations consisting of bulbous swellings (so-called spheroids) along axons ( Figure 1 ). As introduced above, such changes are referred to as axonal spheroid formation or NAD, with the enlargements being identified in terminal synaptic arbors of affected neurons, in white matter and thus involving projection axons, and in proximal regions of axons, and axon collaterals, near the cell body ( Figure 2 ). Spheroids occur distal to the IS (initial segment) of axons and thus are clearly distinguishable from meganeurites which occur proximal to the IS [11] . Ultrastructural studies have shown that these focal enlargements contain collections of tubulovesicular profiles, mitochondria, possible autophagosomes, and dense and multivesicular-type bodies [12] . Occasionally there are also large numbers of neurofilaments, but, in most cases, the accumulation of organellar-type materials predominate, hence the term granular axonal spheroids. Interestingly, axonal spheroids characteristically do not contain the typical lysosomal inclusions found in neuronal perikarya, which are themselves often representative of a particular disease type [e.g. membranous cytoplasmic bodies for primary gangliosidoses, compound bodies for MLIV (mucolipidosis type IV) disease, polymembranous cytoplasmic bodies for NPC (Niemann-Pick type C) disease]. Instead, axonal spheroids found across a wide variety of lysosomal diseases routinely resemble one another, suggesting that their formation is due to a generic defect, possibly one involving axoplasmic transport [5, 9, 12, 13] .
Spheroids have been studied extensively in animal models of lysosomal disorders, where they are found to be abundant in primary ganglioside storage diseases The illustration also summarizes the characteristics of this phenomenon as explored in cat and mouse models [15, 16] .
(GM1 and GM2 gangliosidosis), in MLIV disease and the Niemann-Pick disorders (types A and C), in the glycoproteinosis, α-mannosidosis and so forth [9, [12] [13] [14] [15] [16] . Their incidence and distribution correlate closely with the onset and progression of neurological signs displayed by affected animals, suggesting that they are major players in generating neuronal dysfunction [9] . Spheroids are most readily visualized in neurons using immunocytochemistry to label components trafficked in axons, including enzymes (glutamic acid decarboxylase) as well as calcium-binding proteins (parvalbumin, calbindin) [9, [12] [13] [14] [15] [16] . The use of immunostaining techniques to localize these cell-selective markers in brain tissue from lysosomal diseases has shown that axonal spheroids occur most commonly on neurons that synthesize GABA (γ -aminobutyric acid) as a neurotransmitter, including Purkinje cells, intrinsic neurons of the cerebral cortex (basket cells and other inhibitory neurons) and select GABAergic neuronal populations in basal ganglia and elsewhere in brain. Spheroids are also abundant in numerous areas of the CNS (central nervous system) in human lysosomal diseases such as NPC disease ( [17] , and J. Sikora and M. Elleder, unpublished work). In cats with NPC disease, axonal spheroids occur in massive numbers in inhibitory circuits of the cerebral cortex, in basal ganglia and in cerebellum [15] . Mouse models show somewhat less involvement of the cerebral cortex and basal ganglia, but Purkinje cells are often severely affected [16, 18] .
The similarity between spheroids of lysosomal storage diseases and those found distal to nerve crush or ligation experiments in normal animals [19] has suggested that a defect in retrograde transport may be contributing to their formation. Studies, for example in NPC disease, have also reported that spheroids are initially found in distal portions of axons and subsequently in more proximal areas [15] , suggesting a slow distal-to-proximal migration of spheroid components over time. That distal axonal spheroids tend to be smaller and proximal ones larger in cerebellar Purkinje cells is consistent with this view (Figure 2) . The prominence of spheroids in axons of Purkinje cells and the finding that these cells are also highly prone to die early (but after spheroid formation) in many storage diseases suggests that the two events are linked, with spheroids in some manner compromising Purkinje cell viability. A similar relationship may exist for cerebral cortex, e.g. in human NPC disease, in that spheroids in axons of GABAergic neurons may lead to functional compromise of inhibitory circuits, a view supported by the occurrence of intractable seizures in late disease [20] .
Spheroids may cause the early demise of affected neurons such as Purkinje cells as a consequence of a block in retrograde transport of a component, e.g. a growth factor, critical for cell survival. The importance of retrograde transport of growth factors for sustained survival of neurons has recently received greater attention for a spectrum of neurodegenerative conditions [21] [22] [23] [24] . Similarly, spheroids may compromise the output of affected neurons by blocking or otherwise interfering with action potential propagation [9] or possibly with synaptic vesicle trafficking. Such alternations in the signalling dynamics of neural circuits may in turn increase energy demands on individual neurons, further exacerbating the metabolic stress of storage. Overall, the occurrence of spheroids is poised within the pathogenic cascade to be a major player in generating many of the clinical features of storage diseases, from ataxia, tremors and related movement disorders to seizures. Importantly, the potential role of NAD in a host of other neurodegenerative diseases, from Alzheimer's disease to Huntington's disease, has also recently drawn attention [10, [25] [26] [27] .
Links between the presence of axonal spheroids and neuron death in lysosomal diseases (or indeed, other conditions) have not been systematically explored. Whereas Purkinje cells are known for their exquisite sensitivity to lysosomal compromise and early death, normal Purkinje cells are in fact unique in one feature compared with most neurons: They are remarkably resistant to axotomy [28] [29] [30] . That is, undercutting or lesioning the white matter of the cerebellum does not in itself lead to a chromatolytic reaction in Purkinje cell somata as it would in most other neuron types. Indeed, Purkinje neurons with severed axons survive for long periods of time following complete axotomy, whereas most neurons die [28, 29] . This has been interpreted to suggest that they draw growth factor support locally from the region of the Purkinje cell layer (via axon collaterals) rather than exclusively from their projection nuclei [the DCN (deep cerebellar nuclei) and VN (vestibular nuclei)] [30] . This possibility is reinforced by the discovery that local Purkinje cell axon collaterals become more robust following axotomy and loss of the parent axon. Thus Purkinje cells lacking their parent axons remain viable for extended periods of time as they apparently convert their status as projection neurons into that of local circuit neurons [30] . Such transformation, however, does not compensate for the functional deficits following the loss of their projection input to DCN. The notable resilience of normal Purkinje cells following axotomy makes the prominence of early Purkinje cell death in lysosomal diseases even more intriguing, indeed paradoxical, and raises the question of whether the persistence of a spheroid-possessing long axon and its physiological/metabolic consequences provide a significant burden on survival (Figure 2) . Importantly, however, in diseases such as NPC where Purkinje cell loss is so prominent, spheroids occur earliest in parent axons projecting to DCN, but, before death of these cells, spheroids also form in their collateral branches [15] . This finding is consistent with Purkinje cells receiving a 'double hit' in terms of compromise or loss of retrograde trophic factor support before their demise, coming first from the parent axon and subsequently from its collaterals.
Interestingly, whereas early-onset and prominent Purkinje cell death is characteristic of many lysosomal diseases, not all Purkinje cells are equally vulnerable to early death. In NPC disease, for example, studies in the mouse model have shown a complex pattern of Purkinje cell loss with zebrin II-negative cells dying first, followed only later by zebrin IIpositive Purkinje cells [31] . Additionally, ectopic expression of the small heat-shock protein, HSP25, occurs preferentially in surviving Purkinje cells. The last Purkinje cells to die in NPC disease and other mouse models of lysosomal disorders are those in lobule X [18, 31, 32] . These Purkinje cells, as resident projection neurons of the archicerebellum (vestibulocerebellum) are known to project directly to VN rather than to DCN. Whether such connectivity differences are, in some manner, linked directly to this longer survival is unknown. Interestingly, other genetic conditions not directly related to lysosomal dysfunction, e.g. the pcd (Purkinje cell degeneration) mouse, follow an identical pattern of Purkinje cell loss, complete with spheroids, longer survival of cells in lobule X and changes in specific projection nuclei (VN and DCN) [33, 34] . For pcd, the gene defect is now known to lead to a deficiency of CCP1 (carboxypeptidase 1)/Nna1, a cytosolic protease believed to act downstream of proteasome function [35] . Absence of this enzyme in mice leads to elevations in non-degraded peptides derived from cytosolic and mitochondrial proteins, alterations in autophagy and neuron death. Interestingly, possible downstream alterations in proteasome function have gained attention in lysosomal disease as a component of the pathogenic cascade [1, 4] , in part driven by evidence implicating a role for autophagy in these diseases [36, 37] and by studies showing that autophagy, the proteasome and the endosomal/lysosomal system are intimately coupled in maintaining cell homoeostasis [38] .
As mentioned above, axonal spheroids do not appear to contain lysosomal debris or storage bodies characteristic of the lysosomal disease in question. Indeed, the extent to which lysosomal components are normally found within axons remains controversial and most models favour the retrograde transport of materials in endosomal vesicles (retrosomes or signalling endosomes, autophagosomes) for subsequent fusion with the lysosomal system in perikarya after retrograde transport. A fundamental question involving spheroids is therefore why a disturbance in function of the lysosomal system, presumably confined to neuronal perikarya, would be accompanied by such dramatic cellular pathology in distant parts of the axon. Several possibilities can be cited. First, the lysosomal system defect within perikarya, when sufficiently severe, may restrict the axonal transport of molecular motors such as dynein or related proteins critical for retrograde transport. In support of this hypothesis is the finding that mice lacking such transport proteins (e.g. retrolinkin or BPAG1n4) have been shown to exhibit similar axonal pathology [39, 40] . Secondly, since axonal transport is an energy-requiring activity for the neuron, inadequacy of mitochondrial function or distribution either secondary to transport defects or to increased energy needs secondary to altered firing within the Purkinje cell neural network could, over time, significantly compromise Purkinje cell viability. Thirdly, since many of the vesicular components present in spheroids resemble autophagosomes, and knockout of the autophagy gene Atg7 leads to axonal spheroid formation in the absence of autophagosomes [41] , autophagy dysfunction may underlie spheroid pathology in lysosomal diseases. Finally, autophagy may be induced to occur in exaggerated fashion in some lysosomal diseases as an aberrant salvage mechanism (e.g. see [36] ) and, as a result, lead to an overproduction of autophagosomes that, in turn, cannot be readily cleared from axons. Interestingly, none of these hypotheses has been rigorously tested in lysosomal diseases.
One issue that has become clear in recent years is that the demise of Purkinje cells in NPC disease is cellautonomous. The study of chimaeric mice with nervous systems comprising neurons with, and neurons without, a functional NPC1 protein revealed that normal neurons could not rescue those lacking NPC1, and that the presence of mutant Purkinje cells did not affect the fate of neighbouring normal neurons [42] . Similar results were recently found in mice lacking NPC1 exclusively in Purkinje cells. That is, the presence of normal cerebellar neurons (basket and stellate cells, granule cells, etc.) and glia (including Bergmann glia and oligodendroglia supporting Purkinje cell axons) had no influence over the cell death fate of Purkinje cells lacking NPC1 [43] . Together, these studies provide a convincing view that Purkinje cell death in NPC disease is fully cell-autonomous. The unresolved question is therefore the identification of exactly what it is about the disease cascade in these disorders that makes Purkinje cells so vulnerable to early death. As summarized above, one candidate mechanism surely is the added metabolic burden placed on these cells by a progressively dysfunctional axon.
Rescuing Purkinje cells
A key goal of research on lysosomal diseases is to use knowledge gained in terms of disease cascade analysis to better address the development of new therapies. Studies using an inducible model of a lysosomal disease has revealed that, whereas intraneuronal storage in Purkinje cells (and other neuron types) can be completely reversed under appropriate circumstances, elimination of subsequent cellular changes are not so easily eliminated [44] . Thus, whereas meganeurites on cortical pyramidal neurons readily disappear after storage elimination, many ectopic dendrites do not [44] . This may be due to stabilization of the aberrant dendrites' new synapse formation. For axonal spheroids, many of these also remain as a persisting component in brain even long after the elimination of neuronal storage, and indeed, may even continue to contribute to cerebellar dysfunction [44] . Thus a better understanding of mechanisms underlying NAD and the nature of its subsequent burden on Purkinje cell viability remain important questions relevant to successful therapy development for this disease.
Numerous studies are underway to correct the metabolic defects present in lysosomal diseases, with treatments such as enzyme-replacement therapy showing promise for non-brain correction of those disorders caused by lysosomal enzyme deficiency. For storage diseases with severe brain involvement and particularly for those caused by defects in transmembrane proteins of late endosomes and lysosomes (e.g. NPC1 and MLIV diseases), correction of the metabolic defect in brain has proved very difficult and has spurred attention toward small-molecule therapies that have the ability to cross the blood-brain barrier and affect the metabolic defect and storage. Miglustat (N-butyldeoxynojirimycin), a glycosphingolipid synthesis inhibitor, has shown promise in delaying onset and prolonging life in NPC disease and in animal models has shown particular benefit in slowing the loss of Purkinje cells ( [45] , and C. Davidson and S.U. Walkley, unpublished work). Likewise, the more recently discovered substrate reducer for NPC disease, hydroxypropyl-β-cyclodextrin, also ameliorates storage in Purkinje neurons and slows their loss over time, leading to significant clinical benefit ( [46] , and C. Davidson and S.U. Walkley, unpublished work). In neither case, however, is it presently understood exactly how these drugs provide benefit. In terms of miglustat, for example, a reduction in cholesterol storage in Purkinje neurons following treatment is not believed to occur [45] , suggesting that it may be benefiting these cells through some other mechanism.
Conclusions
Most lysosomal diseases affect the brain and cause complex disease cascades leading to neuronal dysfunction and, in some cases, to neurodegeneration. The formation of axonal spheroids, e.g. in Purkinje cells, is a prominent example of such a cascade event, one that may cause disrupted function of neural circuits for months or years, and later followed by neuron death and additional neurological compromise. Understanding the basis of such cascade events, their relationship to the original gene/protein defect, to the lysosomal system and to the overall integrated state of the neuron and its long-term viability are critical steps towards designing fully effective therapies for these disorders. Insight here, too, can be expected to provide clues for therapy for other neurodegenerative diseases in which axonal compromise has been documented.
